Publication: Safety and immunogenicity of different immunization regimens of cvd 103-hgr live oral cholera vaccine in soldiers and civilians in thailand
dc.contributor.author | Pisit Su-Arehawaratana | en_US |
dc.contributor.author | Preecha Singharaj | en_US |
dc.contributor.author | David N. Taylor | en_US |
dc.contributor.author | Charles Hoge | en_US |
dc.contributor.author | Andrew Trofa | en_US |
dc.contributor.author | Krit Kuvanont | en_US |
dc.contributor.author | Sricharoen Migasena | en_US |
dc.contributor.author | Punnee Pitisuttitham | en_US |
dc.contributor.author | Yu Leung Lim | en_US |
dc.contributor.author | Genevieve Losonsky | en_US |
dc.contributor.author | James B. Kaper | en_US |
dc.contributor.author | Steven S. Wasserman | en_US |
dc.contributor.author | Stanley Cryz | en_US |
dc.contributor.author | Peter Echeverria | en_US |
dc.contributor.author | Myron M. Levine | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Walter Reed Army Institute of Research | en_US |
dc.contributor.other | University of Maryland School of Medicine | en_US |
dc.contributor.other | Berna Biotech AG | en_US |
dc.date.accessioned | 2018-08-10T08:49:55Z | |
dc.date.available | 2018-08-10T08:49:55Z | |
dc.date.issued | 1992-01-01 | en_US |
dc.description.abstract | Attenuated Vibrio cholerae oral vaccine CVD 103-HgR was well tolerated by 324 Thai soldiers and civilians. Most received a single 5 × 10(r) cfu dose, while 40 each received one or two 5 × 109cfu doses. Vibriocidal antibody (the best correlate of immunity) seroconversion was lower in soldiers than civilians (P <.001). Increasing the vaccine dose to 5 × 109cfu raised the geometric mean titer (P <.001). A second 5 × 109cfu dose one week later did not notably increase serocon- versions. Likelihood of seroconversion was inversely correlated with baseline vibriocidal titer (P <.001). CVD 103-HgR caused seroconversion in most subjects with baseline titers <1:40, including 100% of civilians after one 5 × 10(r) cfu dose, 79% of soldiers after one 5 × 109cfu dose, and 45% of soldiers after one 5 × 10scfu dose. In persons with elevated baseline titers, vibriocidal antibody seroconversion is not a sensitive measure of whether vaccine has boosted intestinal immunity; for such subjects, other measurements must be used. Study regimens in endemic areas should use a single 5 × 109cfu dose. © 1992 The University of Chicago. | en_US |
dc.identifier.citation | Journal of Infectious Diseases. Vol.165, No.6 (1992), 1042-1048 | en_US |
dc.identifier.doi | 10.1093/infdis/165.6.1042 | en_US |
dc.identifier.issn | 15376613 | en_US |
dc.identifier.issn | 00221899 | en_US |
dc.identifier.other | 2-s2.0-0026596515 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/22501 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0026596515&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Safety and immunogenicity of different immunization regimens of cvd 103-hgr live oral cholera vaccine in soldiers and civilians in thailand | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0026596515&origin=inward | en_US |